Literature DB >> 21670234

Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy.

Martin S Maron1, Iacopo Olivotto, Caitlin Harrigan, Evan Appelbaum, C Michael Gibson, John R Lesser, Tammy S Haas, James E Udelson, Warren J Manning, Barry J Maron.   

Abstract

BACKGROUND: Whether morphological abnormalities of the mitral valve represent part of the hypertrophic cardiomyopathy (HCM) disease process is unresolved. Therefore, we applied cardiovascular magnetic resonance to characterize mitral valve morphology in a large HCM cohort. METHODS AND
RESULTS: Cine cardiac magnetic resonance images were obtained in 172 HCM patients (age, 42±18 years; 62% men) and 172 control subjects. In addition, 15 HCM gene-positive/phenotype-negative relatives were studied. Anterior mitral leaflet (AML) and posterior mitral leaflet lengths were greater in HCM patients than in control subjects (26±5 versus 19±5 mm, P<0.001; and 14±4 versus 10±3 mm, P<0.001, respectively), including 59 patients (34%) in whom AML length alone, posterior mitral leaflet length alone, or both were particularly substantial (>2 SDs above controls). Leaflet length was increased compared with controls in virtually all HCM age groups, including young patients 15 to 20 years of age (AML, 26±5 versus 21±4 mm; P=0.0002) and those ≥60 years of age (AML, 26±4 versus 19±2 mm; P<0.001). No relation was evident between mitral leaflet length and LV thickness or mass index (P=0.09 and P=0.16, respectively). A ratio of AML length to LV outflow tract diameter of >2.0 was associated with subaortic obstruction (P=0.001). In addition, AML length in 15 genotype-positive relatives without LV hypertrophy exceeded that of matched control subjects (21±3 versus 18±3 mm; P<0.01).
CONCLUSIONS: In HCM, mitral valve leaflets are elongated independently of other disease variables, likely constituting a primary phenotypic expression of this heterogeneous disease, and are an important morphological abnormality responsible for LV outflow obstruction in combination with small outflow tract dimension. These findings suggest a novel role for cardiac magnetic resonance in the assessment of HCM.

Entities:  

Mesh:

Year:  2011        PMID: 21670234     DOI: 10.1161/CIRCULATIONAHA.110.985812

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  86 in total

Review 1.  The role of magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Edward T D Hoey; Mohamed Elassaly; Arul Ganeshan; Richard W Watkin; Helen Simpson
Journal:  Quant Imaging Med Surg       Date:  2014-10

Review 2.  Mitral valve disease--morphology and mechanisms.

Authors:  Robert A Levine; Albert A Hagége; Daniel P Judge; Muralidhar Padala; Jacob P Dal-Bianco; Elena Aikawa; Jonathan Beaudoin; Joyce Bischoff; Nabila Bouatia-Naji; Patrick Bruneval; Jonathan T Butcher; Alain Carpentier; Miguel Chaput; Adrian H Chester; Catherine Clusel; Francesca N Delling; Harry C Dietz; Christian Dina; Ronen Durst; Leticia Fernandez-Friera; Mark D Handschumacher; Morten O Jensen; Xavier P Jeunemaitre; Hervé Le Marec; Thierry Le Tourneau; Roger R Markwald; Jean Mérot; Emmanuel Messas; David P Milan; Tui Neri; Russell A Norris; David Peal; Maelle Perrocheau; Vincent Probst; Michael Pucéat; Nadia Rosenthal; Jorge Solis; Jean-Jacques Schott; Ehud Schwammenthal; Susan A Slaugenhaupt; Jae-Kwan Song; Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2015-10-20       Impact factor: 32.419

3.  Left ventricular outflow tract obstruction with abnormal papillary muscles.

Authors:  Kotaro Oe; Tsutomu Araki; Miho Ohira; Tetsuo Konno; Masakazu Yamagishi
Journal:  J Cardiol Cases       Date:  2014-11-25

4.  Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers.

Authors:  John D Groarke; Patrycja Z Galazka; Allison L Cirino; Neal K Lakdawala; Jens J Thune; Henning Bundgaard; E John Orav; Robert A Levine; Carolyn Y Ho
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2018-10-01       Impact factor: 6.875

Review 5.  Imaging of cardiovascular complications in patients with systemic lupus erythematosus.

Authors:  K Lin; D M Lloyd-Jones; D Li; Y Liu; J Yang; M Markl; J C Carr
Journal:  Lupus       Date:  2015-06-02       Impact factor: 2.911

Review 6.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

Review 7.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

Review 8.  Management of the mitral valve in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Joon Hwa Hong; Anita Nguyen; Hartzell Vernon Schaff
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-05-07

Review 9.  Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

Authors:  Waseem Hindieh; Raymond Chan; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

Review 10.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.